Russia
According to the FDA Report, Russia placed in the top 10 and ranked 2nd after the U.S. in terms of the number of subjects recruited. Russia is the world's 9th country by population (146 mln people), making it a patient pool more than sufficient for a study in almost any indication.
Czech Republic
The leading therapeutic areas in terms of the approvals in 2021 were Oncology, Neurology, Cardiology, Rheumatology. Besides, the country offers competitive advantages for trials in niche areas such as rare and orphan diseases, stem cell and gene therapies.
Hungary
Clinical trials in Hungary are in high demand, as the region is a unique combination of all the important aspects: fast enrollment, low prices, and a remarkable level of quality. Out 50 novel drugs approved by the FDA in 2021, 14 have undergone studies at Hungarian sites.
Spain
Today 145,000 patients are involved in 3,400 clinical trials in progress in Spain. While one out of three trials carried out in Europe already has Spanish participation, the country accounts for a 4.3% share of the global clinical trials activity with oncology as the leading therapeutic area.
Bulgaria
In 2014-2019 Bulgaria was placed in the top 10 and ranked 8th in terms of the number of subjects recruited for studies according to the recent US FDA Report. 13 out of 50 novel drugs approved by the FDA in 2021 underwent studies in Bulgaria.
Romania
Romania has been drawing a lot of interest for international Sponsors. The 12th largest state in Europe offers speedy start-up, specialized healthcare services, experienced personnel with advanced knowledge of eClinical solutions, and record recruitment rates across various therapeutic areas.
Poland
Poland is 10th place in the world by number of research sites (over 1,400). With a population of 38.5 mln people, it boasts successful recruitment rates, reasonable grants, and lower costs per patient than in the U.S., though higher than in Ukraine, Russia or Georgia.
Latvia
Being an EU member since 2004, Latvia boasts a harmonized regulatory and legislative environment for international clinical trials. The majority of studies fall within the therapeutic areas of oncology, neurology, psychiatry, and endocrinology.
Belarus
Belarus is a promising new player. Clinical research professionals are very particular about adhering to GCP standards. Local rules and standards are very close to those mandated by FDA and EMA.
Ukraine
Recruitment shows a significant number of eligible patients, including treatment-naïve ones. According to the MoH of Ukraine, leading therapeutic areas in 2020 are Oncology, Psychiatry, Neurology, Gastroenterology, and Hematology. The RA process takes up to 60 calendar days.

本地经验 全球成果

2005年以来,在东欧提供高质量临床研究服务

Contact our regional office
Operations in 20 countries:

Latvia
Poland
Romania
Hungary
Czech Republic
Spain
Ukraine
Bulgaria
the Netherlands
Georgia
Estonia
Lithuania
Belarus
Serbia
Russia
Kazakhstan
Croatia
Bulgaria
Moldova

More Countries
An official member of the European CRO Federation
up to
4x
faster enrollment
access to
2,100
leading research sites
we have enrolled
58,937
patients up to date
we deliver
EMA/FDA
acceptable data
为每个项目量身定制的方法 ●
无论身处何地,注册速度提高1.5倍 ●
只需一封邮件或是一通电话,随时为您提供服务 ●

全面临床试验服务

我们从不在质量、时间和预算方面作出任何妥协。在这三方面,我们都提供最好的服务。这一理念建立在专业团队多年积累的经验和完善的程序基础之上。

Gatis Claucans
Director of Clinical Operations, OCT Latvia

2005年以来,我们在29个治疗领域进行了300多项研究

所有治疗领域

OCT临床救援

救援研究是一项特殊的专业技能

当临床试验遇到障碍时,我们随时准备介入。每次我们进行一项积极的试验时,我们的专家都会制定研究救援计划,着重解决当前的瓶颈和研究挑战,并加快研究进度使其重回正轨。

欢迎致电

我们的客户

Other partners

媒体室

OCT Clinical在路上

联系OCT Clinical

Thank you for your request!
Our team will respond to you within 24 hours.